Blar i Bergen Open Research Archive på forfatter "Solli, Kristin Klemmetsby"
-
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
Solli, Kristin Klemmetsby; Opheim, Arild; Latif, Zill-E-Huma; Krajci, Peter; Saltyte Benth, Jurate; Kunoe, Nikolaj; Tanum, Lars Håkon Reiestad (Journal article; Peer reviewed, 2020)Background and aim: Extended-release naltrexone (XR-NTX) is an underused treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short-term ... -
Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial
Solli, Kristin Klemmetsby; Kunøe, Nikolaj; Latif, Zill-E-Huma; Haase, Kamni Sharma; Opheim, Arild; Krajci, Peter; Gaulen, Zhanna; Saltyte Benth, Jurate; Tanum, Lars Håkon Reiestad (Journal article; Peer reviewed, 2019)Background and objective: Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of ... -
‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study
Brenna, Ida Halvorsen; Marciuch, Anne; Birkeland, Bente; Veseth, Marius; Røstad, Bente; Løberg, Else-Marie; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad; Weimand, Bente (Journal article; Peer reviewed, 2022)Background: Extended-release naltrexone (XR-NTX), an opioid antagonist, has demonstrated equal treatment outcomes, in terms of safety, opioid use, and retention, to the recommended OMT medication buprenorphine. However, ... -
Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
Marciuch, Anne; Brenna, Ida Halvorsen; Weimand, Bente; Solli, Kristin Klemmetsby; Tanum, Lars Håkon Reiestad; Røstad, Bente; Birkeland, Bente (Journal article; Peer reviewed, 2022)Background The opioid antagonist extended-release naltrexone (XR-NTX) in the treatment of opioid use disorder (OUD) is effective in terms of safety, abstinence from opioid use and retention in treatment. However, it is ... -
Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial
Opheim, Arild; Gaulen, Zhanna; Solli, Kristin Klemmetsby; Latif, Zill-E-Huma; Fadnes, Lars T.; Saltyte Benth, Jurate; Kunøe, Nikolaj; Tanum, Lars Håkon Reiestad (Journal article; Peer reviewed, 2021)Background and Objectives: Compare the risk of relapse to heroin and other illicit opioids among opioid-dependent patients receiving treatment with extended-release naltrexone (XR-NTX) or buprenorphine-naloxone ... -
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial
Opheim, Arild; Saltyte Benth, Jurate; Solli, Kristin Klemmetsby; Kloster, Pia Synnøve; Fadnes, Lars T.; Kunøe, Nikolaj; Gaulen, Zhanna; Tanum, Lars Håkon Reiestad (Journal article; Peer reviewed, 2023)Background and objective First study to assess any compensatory increase in use of non-opioid illicit substances and alcohol in opioid dependent patients randomized to treatment with extended-release naltrexone (XR-NTX) ...